Despite a more discerning financing environment, 2023 saw bright spots with substantial opportunities for clinical stage biotechs.
Early stage licensing deals continued to take the lion’s share of deal flow, however, biopharma companies with lead programs in Phase II trials saw higher than average deal sizes.
While Q4 licensing and partnership activity saw deal count continue to taper, total capital raised was the highest in history. The average Seed and Series A deal size reached levels not seen since 2021 and 2019. Remarkably, total M&A deal value was higher in Q4, even with fewer deals.
J.P. Morgan’s biopharma licensing and venture report explores the developments in therapeutics and offers insight into the industry trends that shaped 2023. The report, powered by DealForma, highlights:
Read the full report to better understand these dealmaking trends.
Head of Life Sciences, Innovation Economy, Commercial Banking, J.P. Morgan
Head of Healthcare VC Coverage, Commercial Banking, J.P. Morgan
Feb 14, 2024
The January CPI report offered an unwelcome surprise to the upside and sent markets tumbling.
Feb 14, 2024
Across several global innovation hubs, leaders of venture-backed, high-growth companies are hopeful about their prospects.
Feb 09, 2024
Megacap stocks just delivered another round of stellar results. What did we learn and can the momentum continue?
Feb 08, 2024
Five Easy Pieces: on Magnificent 7 stocks, open source large language models, the No Labels movement, the Armageddonists and bottom-fishing in Chinese equities.
Feb 05, 2024
The U.S. economy added a higher-than-expected 353,000 jobs in the first month of the year. Discover the details of the jobs report and the implications for Fed policy in 2024.
Feb 02, 2024
The Fed. Big rally jitters. Elections. Markets may have seen this movie before.
Feb 01, 2024
The Federal Reserve held interest rates steady and described an uncertain path toward rate cuts in 2024. Read more about the implications of the Fed’s latest decision.
Jan 31, 2024
Our report explores major trends impacting the innovation economy, including the venture fundraising, investment and exit environment.
You're now leaving J.P. Morgan
J.P. Morgan’s website and/or mobile terms, privacy and security policies don’t apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan isn’t responsible for (and doesn’t provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan name.